Drug Profile
Lacosamide controlled release - Adamas Pharmaceuticals
Alternative Names: ADS 4101; Lacosamide extended release capsuleLatest Information Update: 26 Sep 2022
Price :
$50
*
At a glance
- Originator Adamas Pharmaceuticals
- Class Acetamides; Analgesics; Antiepileptic drugs; Benzene derivatives; Neuroprotectants; Small molecules
- Mechanism of Action CRMP2 protein modulators; Glycine gated NMDA receptor antagonists; Sodium channel antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
- Available For Licensing Yes - Epilepsy
Highest Development Phases
- Discontinued Epilepsy
Most Recent Events
- 26 Sep 2022 Discontinued - Phase-I for Epilepsy (In volunteers) in USA (PO) (Supernus pipeline; September 2022)
- 24 Nov 2021 Adamas Pharmaceuticals has been acquired by Supernus Pharmaceuticals
- 22 Jul 2021 Adamas Pharmaceuticals has patent protection for ADS 4101 in Japan and USA (Adamas Pharmaceuticals website, April 2021)